Kyverna Therapeutics remains firmly in the clinical stage without commercial products, emphasizing its proprietary CAR T-cell platform targeting rare autoimmune diseases. The company’s lead candidate, miv-cel, is in Phase 2 for stiff person syndrome, with other candidates for conditions like generalized myasthenia gravis. While Kent’s net losses deepened in 2025, strong liquidity from recent equity raises supports ongoing R&D. Nonetheless, significant regulatory uncertainties especially around CAR T therapies’ safety profiles and competitive pressures pose material challenges ahead.